title: The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy.
abstract: OBJECTIVE
  The aim of this study was to evaluate the efficacy and safety of zoledronic acid compared with placebo in preventing bone mineral density (BMD) loss and suppressing bone markers when initiated during the first year of androgen deprivation therapy in patients with locally advanced prostate cancer.
  
  
  METHODS
  Patients were randomized to receive zoledronic acid 4 mg or placebo intravenously every 3 months. Lumbar spine (LS) and total hip BMD was measured using dual-energy x-ray absorptiometry at baseline and at week 52. N-telopeptide (NTX) and bone-specific alkaline phosphatase (BSAP) were evaluated at baseline and every 12 weeks. Safety assessments were performed throughout the study.
  
  
  RESULTS
  Efficacy analyses included 106 patients and 109 patients in the zoledronic acid and placebo groups, respectively. At week 52, the least squares mean BMD percentage differences were 6.7% for LS and 3.7% for total hip (P < 0.0001 for both). In the zoledronic acid group, decreases in NTX ((-)14% to (-)28%) and BSAP ((-)31% to (-)37%) levels were significant and sustained; changes in NTX levels and LS BMD (r = (-)0.25; P = 0.04) and in BSAP levels and hip BMD (r = (-)0.28; P = 0.02) were significantly correlated. Only traumatic fractures were reported for 2 and 3 patients receiving zoledronic acid and placebo, respectively. One patient in each group experienced acute renal failure. Osteonecrosis of the jaw was not reported.
  
  
  CONCLUSIONS
  Zoledronic acid (4 mg intravenously every 3 months) was safe and effective in preventing bone loss and reducing bone turnover in patients with prostate cancer when initiated during the first year of androgen deprivation therapy; patients with low baseline BMD experienced the greatest benefit.
authors.affiliation: Staten Island Urological Research, NY 10304, USA. risraeli@urocancer.com
authors.forename: Ron S
authors.initials: RS
authors.lastname: Israeli
authors.forename: Steven J
authors.initials: SJ
authors.lastname: Rosenberg
authors.forename: Daniel R
authors.initials: DR
authors.lastname: Saltzstein
authors.forename: James E
authors.initials: JE
authors.lastname: Gottesman
authors.forename: Howard R
authors.initials: HR
authors.lastname: Goldstein
authors.forename: Gerald W
authors.initials: GW
authors.lastname: Hull
authors.forename: Diep Nh
authors.initials: DN
authors.lastname: Tran
authors.forename: Ghulam M
authors.initials: GM
authors.lastname: Warsi
authors.forename: Leo V
authors.initials: LV
authors.lastname: Lacerna
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D015415:Biomarkers / Q000032:analysis / Q000378:metabolism; D015519:Bone Density / Q000187:drug effects*; D050071:Bone Density Conservation Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001842:Bone and Bones / Q000378:metabolism; D004164:Diphosphonates / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000139:chemically induced / Q000517:prevention & control*; D010919:Placebos / Q000008:administration & dosage; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D016896:Treatment Outcome; D000077211:Zoledronic Acid
chemical_list: D000726:Androgen Antagonists; D015415:Biomarkers; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D010919:Placebos; D000077211:Zoledronic Acid